Roche Unveils Digital PCR System To Identify Rare And Emerging Disease Mutations

Swiss drug major Roche (RHHBY) announced Tuesday the launch of the Digital LightCycler System, a digital polymerase chain reaction or PCR system, to help better understand the nature of a patient's cancer, genetic disease or infection.

The system will be available in 15 countries worldwide in 2022 with plans to launch into more countries in the near future. The system will be CE-marked and has an FDA 510(k) exempt status.

Digital LightCycler System is Roche's first digital PCR system. The new next-generation diagnostics platform, which detects disease, is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.

The System is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in areas such as oncology and infectious diseases.

It will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
Follow RTT